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Evaluation of Tumor Markers in Asthma Patients
Background: Although tumor markers have been used as biomarkers for monitoring response to therapy and
detecting early relapse in malignancies, it is well known that most tumor marker increases are not specific
enough to be used for diagnosis of cancer.
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Aim: The aim of this study was to investigate the serum concentrations of α-fetoprotein (AFP),
carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, CA 125, CA 15-3 and IgE in asthma patients.
Materials and Methods: Thirty-five newly diagnosed asthmatic patients and 14 healthy subjects were
included into the study. Blood samples were drawn from antecubital vein of asthma patients and control
subjects. Serum AFP, CEA, CA 125, CA 15-3 and CA 19-9 levels were determined by chemiluminescent and
IgE levels by electrochemiluminescent immunometric method on automatic hormone analyzers.
Results: Serum levels of AFP, CEA, CA 19-9, CA 125, and CA 15-3 of asthma patients were not significantly
different when compared with the control group. In asthma patients, there was a significant negative
correlation between serum IgE and CA 125 (r = -0.401; p = 0.017) and a positive correlation between CA
125 and CA 15-3 (r = 0.368; p = 0.029).
Conclusions: We concluded that in asthma patients’ sera, AFP, CEA, CA 125, CA 19-9 and CA 15-3 levels
were not different from control subjects. Elevation in any of these tumor markers in asthma patients should
be a sign for clinicians to evaluate patients for additional diseases.
Key Words: Asthma, AFP, CA 125, CA 15-3, CA 19-9, CEA

Ast›m Hastalar›nda Tümör Belirteçlerinin De¤erlendirilmesi
Amaç: Tümör belirteçleri malignitelerin relaps›n›n erken tespitinde ve tedaviye cevab›n izlenmesinde
biyobelirteçler olarak kullan›lmas›na ra¤men, ço¤u tümor belirtecinin kanser tan›s›nda kullanmak için yeterince
spesifik olmad›¤› bilinmektedir. Biz bu çal›ﬂmada ast›ml› hastalarda serum AFP, CEA, CA 19-9, CA 125, CA 153 ve IgE düzeylerini araﬂt›rmay› amaçlad›k.
Yöntem ve Gereç: Bu çal›ﬂmaya 35 yeni tan› konulmuﬂ ast›m hastas› ve 14 sa¤l›kl› birey dahil edildi. Ast›ml›
ve kontrol bireylerinin antekübital venlerinden kan örnekleri al›nd›. Otomatik hormon analizöründe, serum
AFP, CEA, CA 125, CA 15-3 ve CA 19-9 düzeyleri kemiluminesans, IgE düzeyleri de elektrokemilüminesans
immünometrik metodla ölçüldü.
Bulgular: Ast›m hastalar›n›n serum AFP, CEA, CA 125, CA 15-3 ve CA 19-9 düzeyleri kontrol grubundan
istatistiksel olarak farkl› de¤ildi. Ast›m hastalar› grubunda IgE ile CA 125 aras›nda negatif (r = -0,401; p =
0,017) ve CA 125 ile CA 15-3 aras›nda ise anlaml› pozitif korelasyon oldu¤u gözlendi (r = 0,368; p = 0,029).
Sonuç: Ast›m hastalar›n›n serumlar›nda AFP, CEA, CA 125, CA 19-9 ve CA 15-3 düzeyleri kontrol grubundan
farkl› olmad›¤› sonucuna vard›k. Ast›ml› hastalarda bu tümör belirteçlerindeki herhangi bir yükseklikli¤in tespit
edilmesi durumunda klinisyenlerin, ast›mdan baﬂka ilave hastal›klar›da göz önünde bulundurmalar› gerekti¤ini
düﬂünmekteyiz.
Anahtar Sözcükler: Ast›m, AFP, CA 125, CA 15-3, CA 19-9, CEA
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Although tumor markers have been introduced to clinical use as biomarkers for
monitoring response to therapy and detecting early relapse in malignancies, it has been
observed that most tumor marker increases in normal or benign conditions are not
specific enough to be used for diagnosis of cancer (1).
α-Fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125),
cancer antigen 19-9 (CA 19-9) and cancer antigen 15-3 (CA 15-3) are commonly used
tumor markers in monitoring and screening of various tumors of liver, pancreas,
gastrointestinal system, ovary and breast. However, these tumor markers are not
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specific for these malignancies. Serum AFP levels are
elevated in patients with benign liver conditions such as
cirrhosis and hepatitis (1). CEA has been found to be
elevated in some patients having benign conditions, such
as cirrhosis, pulmonary emphysema, rectal polyps, benign
breast diseases, and ulcerative colitis (1). CA 125 levels
are increased in endometriosis, adenomyosis, uterine
fibroids, ovarian cysts, salpingitis, peritonitis, pleuritis,
pericarditis, alcoholic hepatitis, and the first trimester of
normal pregnancy (2). CA 19-9 is an intracellular
adhesion molecule, and elevated levels have been
reported in patients with benign conditions such as
cirrhosis, cholestasis, cholangitis, and pancreatitis (3).
Elevated levels of CA 15-3 have been reported in benign
breast and liver diseases (1).
The relation between various tumor markers and nonneoplastic diseases of the lung, such as asthma, warrants
investigation since high levels of serum tumor markers
might indicate a tumoral formation in a patient with
benign pulmonary disease and can alert the pulmonary
specialist to evaluate the patient. On the other hand, a
benign lung disease with an increased serum tumor
marker can lead the clinician to the sophisticated and
unnecessary diagnostic procedures.
In the asthmatic airway, shedding of the bronchial
epithelium with selective loss of columnar epithelial cells
from their attachment to basal cells is a characteristic
feature (4). Airway epithelium is an important source of
cytokines, growth factors, and chemokines and exhibits
an altered profile of adhesion molecules expression (5).
Thus, it is not surprising to determine elevated levels of
different tumor markers in asthmatic patients. The aim of
this study was to investigate the serum levels of AFP,
CEA, CA 19-9, CA 125, and CA 15-3 in patients with
different stages of asthma.

Materials and Methods
Patient population
Thirty-five newly diagnosed asthmatic patients (17
women) aged 10–66 years (mean: 38.4 years) and 14
healthy subjects of similar age as a control group were
included into the study. None of the patients had received
inhaled or orally administered corticosteroids or any
other anti-inflammatory drugs such as sodium
cromoglycate or nedocromil sodium in the previous four
months. The patients used inhaled beta-2 stimulants only
210
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when necessary. Patients had shown no signs of upper or
lower respiratory disease for at least two weeks before
entering the study.
Study design
At the initial visit a full history was obtained. Skin
prick tests to common aeroallergens were performed and
blood was drawn for measurement of total IgE.
Asthmatic subjects measured their peak expiratory flow
(PEF) in the morning and evening using a Peak
Flowmeter (Vitalograph Alpha, USA) and recorded results
on a diary card.
Definition of asthma patients
Asthma is a chronic inflammatory disorder associated
with an increase in airway hyperresponsiveness that leads
to recurrent and often reversible episodes of wheezing,
breathlessness, chest tightness, and coughing, particularly
at night or in the early morning. All patients satisfied the
Global Initiative for Asthma (GINA) criteria for asthma
(6).
Classification of Asthma Severity by Clinical
Features before Treatment (GINA)
The severity of a patient’s asthma may be classified
into one of these four steps based on the clinical features
present before treatment is begun. No step 4 patients
were present in our study.
Step 1: Intermittent
• Symptoms less than once a week
• Brief exacerbations
• Nocturnal symptoms not more than twice a month
• Forced expiratory volume in 1 second (FEV1) or
(PEF) ≥ 80% predicted, PEF or FEV1 variability < 20%
Step 2: Mild Persistent
• Symptoms more than once a week but less than
once a day
• Exacerbations may affect activity and sleep
• Nocturnal symptoms more than twice a month
• FEV1 or PEF ≥ 80% predicted, PEF or FEV1
variability 20-30%
Step 3: Moderate Persistent
• Symptoms daily
• Exacerbations may affect activity and sleep
• Nocturnal symptoms more than once a week
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• Daily use of inhaled short-acting beta-2-agonist
• FEV1 or PEF 60-80% predicted, PEF or FEV1
variability > 30%
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40
35
30
25

Step 4: Severe Persistent

20

• Symptoms daily

15
10

• Frequent exacerbations
• Frequent nocturnal asthma symptoms
• Limitation of physical activities
• FEV1 or PEF ≤ 60% predicted, PEF or FEV1
variability > 30%
Methods
Blood samples were drawn from antecubital vein of
asthma patients and control subjects. All blood samples
were centrifuged for 10 min at 1500 g and sera were
stored at -40 oC until analysis. All samples were processed
within one month.
Biochemical assay
Serum AFP, CEA, CA 125, CA 19-9 and CA 15-3
levels were determined by chemiluminescent
immunometric methods in each group on an automatic
hormone analyzer (Immulite, DPC, Los Angeles, USA).
Serum
IgE
level
was
determined
by
electrochemiluminescence immunoassay in each group on
an automatic hormone analyzer (Roche Modular Analytics
Hitachi E 170, Japan).
Statistical analysis
Data were expressed as the mean ± SD. The un-paired
Student’s t test was used to evaluate the significance of
difference between asthma (all patients) and control
groups. The significance of difference among all steps of
asthma and control groups was analyzed using analysis of
variance (ANOVA), and if the F value was found to be
significant, differences between means was then analyzed
using the post-ANOVA (Tukey) test. Correlations between
parametric and non-parametric variables were assesed
using Pearson and Spearman’s correlation analysis
respectively. Values of p < 0.05 were considered as
statistically significant.

5
0
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Figure 1. Serum levels of AFP, CEA, CA 125, CA 15-3 and CA 19-9 in
control subjects (first column) and asthma patients (second
column).

Results
Serum levels of AFP, CEA, CA 125, CA 15-3 and CA
19-9 of all asthma patients and control subjects are
shown in Figure 1. The differences between serum levels
of CEA (2.7 ± 1.8 ng/ml), CA 19-9 (12.0 ± 8.9 U/ml),
CA 125 (8.3 ± 4.8 U/ml), AFP (1.6 ± 0.6 U/ml), and CA
15-3 (25.4 ± 9.0 U/ml) in asthma patients and in those
of control subjects (CEA = 2.2 ± 0.7 ng/ml; CA 19-9 =
8.5 ± 3.9 U/ml; CA 125 = 8.6 ± 4.5 U/ml; AFP = 2.0 ±
0.8; CA 15-3 = 20.7 ± 5.7) were not statistically
significant (P > 0.05).
As shown in Table 1, we also evaluated serum levels
of AFP, CA 15-3, CEA, CA 19-9 and CA 125 in patients
based on asthma severity. Serum levels of AFP, CA 15-3,
CEA, CA 125 and CA 19-9 in step 1, 2, 3 asthma patients
and control subjects were not significantly different (P >
0.05).
In asthma patients, serum total IgE levels ranged
from 1 to 1450 U/mL (median 131 U/mL). Reference
range for IgE was 0-200 U/mL. In asthma patients, there
was a significant negative correlation between serum IgE
and CA 125 levels (r = -0.401; p = 0.017) and a positive
correlation between serum CA125 and CA 15-3 levels (r
= 0.368; p = 0.029) (Figure 2).
Discussion
Biological and technical advances have led to greatly
increased research and development in the area of tumor
biomarkers. Despite intensive studies, there is not yet a
specific tumor marker for known tumors.
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Table 1. Serum levels of tumor markers in control subjects and asthma patients.
Serum levels in asthma patients
Tumor markers

AFP (U/mL)

Control
( n=14)

2.5 ± 1.1

All Patients
(n = 35)

Step 1
(n = 7)

Step 2
(n =14)

Step 3
(n =14)

1.6 ± 0.6

1.8 ± 0.7

1.4 ± 0.3

1.6 ± 0.7

Reference
range

0.56 – 2.6

CEA (ng/mL)

2.2 ± 0.7

2.7 ± 1.8

2.8 ± 0.3

2.5 ± 2.3

2.7 ± 1.8

0.21 – 6.3

CA 125 (U/mL)

8.6 ± 4.5

8.3 ± 4.8

7.0 ± 5.1

8.2 ± 4.5

9.1 ± 5.2

2.6 – 18.0

CA 15-3 (U/mL)

16.8 ± 5.7

25.4 ± 9.0

25.6 ± 10.8

28.4 ± 8.1

22.4 ± 8.5

9.0 – 51.0

CA 19-9 (U/mL)

8.5 ± 3.9

12.0 ± 8.9

8.6 ± 5.6

12.7 ± 8.9

13 ± 10.3

0.0 – 33.0

Values are given as mean ± SD.
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that remodeling of the airways is caused by thickening of
the subepithelial layer and this is associated with an
increase of myofibroblasts (9). In light of the literature
about the pathophysiology of asthma and tumors, it is not
surprising to measure elevated serum concentrations of
some bioactive molecules like growth factors, cytokines
and metalloproteinases. The tumor markers that we have
measured in our study were not related to asthma
significantly. This point is important, especially for
clinicians, when evaluating asthma patients with elevated
tumor markers.

Biological features of a tumor are different from
normal tissues. In neoplasia, progressive biological
heterogeneity with transient characteristics of expression
is a characteristic of a tumor cell (7). Biological
heterogeneity is present both among cells within a tumor
at a given time point and in cells during the development
of tumors from earlier to later time points (8).

CEA, an oncofetal glycoprotein, is a marker for
colorectal, gastrointestinal, lung and breast carcinoma
(10-13). Maeda and co-workers (14) have reported that
CEA concentration is elevated in asthma patients with
mucoid impaction in comparison with patients without
mucoid impaction and healthy volunteers. In the present
study, there were no asthma patients with mucoid
impaction in our study groups, and serum CEA levels in
asthma patients were not different from the control
group and were within reference range for the normal
population.

Cytokines, metalloproteinases, some growth factors
and other molecules may play important roles in
remodeling of asthmatic patients’ airway tissues, many
different tumors, and inflammatory processes. Airway
smooth muscle hyperplasia is an important pathologic
feature of chronic asthma that contributes to airway
obstruction and exaggerated bronchoconstriction. In
asthmatic patients, chronic inflammation causes marked
remodelling of the structure of the bronchi. Bronchial
biopsy specimens from asthmatic patients have indicated

Elevated levels of CA 19-9, an intracellular adhesion
molecule, occur primarily in patients with pancreatic and
biliary tract cancers (3). Takayama and co-workers (15)
studied CA 19-9 in 156 patients with benign pulmonary
disease (11 with bronchial asthma) and found elevated
levels of CA 19-9 in 27.3% of patients with asthma.
However, in our study, serum CA 19-9 levels in asthma
patients were not different than those of control subjects
and were within reference range of the normal
population.

Figure 2. Correlation between CA 125 and CA 15-3 in asthma patients.
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AFP, an oncofetal glycoprotein, is a marker of
hepatocellular and germ cell carcinoma; CA 125 is a
marker of ovarian and endometrial carcinoma; and CA
15-3 is a marker of breast carcinoma (1). In our study,
serum AFP, CA 125 and CA 15-3 levels in asthma
patients also did not differ from those of the control
group. There was no statistical difference between steps
in AFP, CA 125 and CA 15-3 levels. No step 4 patients
were present in our study. To the best of our knowledge,
this study is the first to investigate CA 125, CA 15-3 and
AFP levels in asthma patients since a literature search at
the time of manuscript preparation (using asthma and CA
125; asthma and CA 15-3; asthma and AFP as key words

August 2006

in PubMed) produced no study measuring and discussing
CA 125, CA 15-3 and AFP in asthma cases. In the present
study, we found that there was a significant negative
correlation between serum IgE and CA 125 and a positive
correlation between CA 125 and CA 15-3 in asthma
patients. Further studies are needed to establish the
interaction between these tumor markers in asthma
patients.
We conclude that in asthma patients’ sera, AFP, CEA,
CA 125, CA 19-9, and CA 15-3 are not elevated
significantly. Thus, elevation in any of these tumor
markers in asthma patients should be a sign for clinicians
to evaluate patients for additional diseases.
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